FDA issues warning on pets' reactions to common flea medicine



[ad_1]

FRIDAY, Sept. 21, 2018 (HealthDay News) – Flea medications protect your pet, but some pets may have serious side effects from products containing isoxazoline, warn US health officials.

Although most dogs and cats handle this powerful pesticide very well, others can have serious reactions, the US Food and Drug Administration said Thursday.

Isoxazoline-based products have been associated with neurological reactions, including muscle tremors, loss of muscle control, and seizures. Most dogs and cats do not have bad reactions to these products, but seizures can occur even though they have never happened before, the agency said.

The FDA approved drugs in this class are:

  • Bravecto
  • Credelio
  • Nexgard
  • Simparica

Although these products can be used safely for most dogs and cats, the FDA has advised you to check with your veterinarian about your pet's medical history to make sure these products are safe for your pet.

The FDA has stated that many types of tick and flea products are available. Discussing options with your veterinarian can help you make an informed choice that best suits your pet.

If your cat or dog has symptoms of isoxazoline, talk to your veterinarian, the FDA said.

As the agency monitors the negative side effects of these products, you and your veterinarian can report the cases to the product manufacturer, who will forward this report to the FDA. You can also report problems directly to the agency.

To report a problem or get more information about the product you are using, contact the following companies directly:

  • Merck Animal Health (Bravecto): 800-224-5318
  • Animal Health Elanco (Credelio): 888-545-5973
  • Merial (Nexgard): 888-637-4251
  • Zoetis (Simparica): 888-963-8471

If you or your veterinarian have additional questions, contact the FDA at [email protected] or call 240-402-7002.

More information

To report an issue related to isoxazoline, consult the US Food and Drug Administration.

SOURCE: US Food and Drug Administration, press release, September 20

Last update:

[ad_2]
Source link